Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) has been assigned an average recommendation of “Hold” from the eight ratings firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $17.00.

TTPH has been the subject of several research reports. Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 price target for the company in a report on Saturday, September 23rd. BMO Capital Markets raised their price target on shares of Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the stock an “outperform” rating in a report on Wednesday, October 4th. HC Wainwright restated a “buy” rating and set a $17.00 price target on shares of Tetraphase Pharmaceuticals in a report on Tuesday, December 5th. Finally, ValuEngine cut shares of Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st.

Tetraphase Pharmaceuticals (TTPH) traded up $0.03 during mid-day trading on Thursday, hitting $6.34. 329,906 shares of the company traded hands, compared to its average volume of 342,316. Tetraphase Pharmaceuticals has a twelve month low of $3.57 and a twelve month high of $9.93.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) EPS for the quarter, hitting the consensus estimate of ($0.63). The business had revenue of $4.10 million during the quarter, compared to analysts’ expectations of $1.59 million. Tetraphase Pharmaceuticals had a negative net margin of 1,382.33% and a negative return on equity of 88.27%. The firm’s quarterly revenue was up 355.6% compared to the same quarter last year. During the same period last year, the company posted ($0.58) earnings per share. analysts anticipate that Tetraphase Pharmaceuticals will post -2.88 EPS for the current year.

In other Tetraphase Pharmaceuticals news, Director L Patrick Gage bought 3,880 shares of Tetraphase Pharmaceuticals stock in a transaction on Wednesday, November 29th. The stock was purchased at an average cost of $6.45 per share, for a total transaction of $25,026.00. Following the completion of the purchase, the director now directly owns 38,880 shares of the company’s stock, valued at $250,776. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Jacques Dumas sold 7,167 shares of Tetraphase Pharmaceuticals stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $6.21, for a total transaction of $44,507.07. The disclosure for this sale can be found here. 5.50% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of TTPH. Schwab Charles Investment Management Inc. lifted its stake in Tetraphase Pharmaceuticals by 0.7% in the second quarter. Schwab Charles Investment Management Inc. now owns 129,681 shares of the biopharmaceutical company’s stock valued at $925,000 after acquiring an additional 874 shares during the last quarter. Rhumbline Advisers lifted its stake in Tetraphase Pharmaceuticals by 5.7% in the second quarter. Rhumbline Advisers now owns 51,633 shares of the biopharmaceutical company’s stock valued at $368,000 after acquiring an additional 2,780 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Tetraphase Pharmaceuticals by 3.3% in the second quarter. Bank of New York Mellon Corp now owns 194,144 shares of the biopharmaceutical company’s stock valued at $1,384,000 after acquiring an additional 6,247 shares during the last quarter. AXA acquired a new stake in Tetraphase Pharmaceuticals in the second quarter valued at approximately $132,000. Finally, Alliancebernstein L.P. lifted its stake in Tetraphase Pharmaceuticals by 6.9% in the second quarter. Alliancebernstein L.P. now owns 59,200 shares of the biopharmaceutical company’s stock valued at $422,000 after acquiring an additional 3,800 shares during the last quarter. Hedge funds and other institutional investors own 58.15% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://theolympiareport.com/2018/01/21/tetraphase-pharmaceuticals-inc-ttph-receives-17-00-consensus-pt-from-analysts.html.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.